Magenta Therapeutics Share Price (NASDAQ: DNTH)

$23.5

▲

0.8

(3.52%)

Live

Last updated on August 20, 2025 at 11:37 PM IST

$₹

Check the interactive Magenta Therapeutics Stock chart to analyse performance

Magenta Therapeutics stock performance

as on August 20, 2025 at 11:37 PM IST

Today's Low:$22.53
Today's High:$23.50
$23.50
4.13%
Downside
Day's Volatility :4.13%
Upside
0.0%
52 Weeks Low:$13.37
52 Weeks High:$32.27
$23.50
43.13%
Downside
52 Weeks Volatility :58.58%
Upside
27.18%

Magenta Therapeutics Stock Returns

Period	Magenta Therapeutics Inc	Index (Russel 2000)
3 Months	21.44%	0.0%
6 Months	-2.44%	0.0%
1 Year	-21.43%	0.0%
3 Years	-14.78%	-9.6%

Magenta Therapeutics Inc Key Stats

Check Magenta Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$22.7
Open	$20.805
Today's High	$23.6
Today's Low	$22.53
Market Capitalization	$674.7M
Today's Volume	$493.2K
52 Week High	$32.27
52 Week Low	$13.365
Revenue TTM	$4.9M
EBITDA	$-129.8M
Earnings Per Share (EPS)	$-3.27
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-34.71%

Stock Returns calculator for Magenta Therapeutics Stock including INR - Dollar returns

The Magenta Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Magenta Therapeutics investment value today

Current value as on today

₹84,979

Returns

₹15,021

(-15.02%)

Returns from Magenta Therapeutics Stock

₹18,910 (-18.91%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards Magenta Therapeutics Stock

100%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Magenta Therapeutics Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Magenta Therapeutics Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Magenta Therapeutics(by analysts ranked 0 to 5 stars)

Magenta Therapeutics Share Price Target

What analysts predicted

Upside of 120.34%

Target:

$51.78

Current:

$23.50

Magenta Therapeutics share price target is $51.78, a slight Upside of 120.34% compared to current price of $23.50 as per analysts' prediction.

Magenta Therapeutics Stock Insights

Price Movement
In the last 7 days, DNTH stock has moved up by 9.2%
Decreasing Revenue
Revenue is down for the last 4 quarters, 2.17M → 193.0K (in $), with an average decrease of 44.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 7 quarters, -10.56M → -31.62M (in $), with an average decrease of 20.9% per quarter
DNTH vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 84.7%
DNTH vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.3% return, outperforming this stock by 122.8%
Price to Sales
ForDNTH every $1 of sales, investors are willing to pay $166.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.1 for every $1 of sales.

Magenta Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY21

FY22

FY23

FY24

	FY21	Y/Y Change
Revenue	$1.5M	-
Net Income	$-13.1M	↓ 82.51%
Net Profit Margin	-888.14%	-

	FY22	Y/Y Change
Revenue	$6.4M	↑ 334.76%
Net Income	$-28.5M	↑ 117.22%
Net Profit Margin	-443.76%	↑ 444.38%

	FY23	Y/Y Change
Revenue	$2.8M	↓ 55.96%
Net Income	$-43.6M	↑ 52.95%
Net Profit Margin	-1.5K%	↓ 1097.46%

	FY24	Y/Y Change
Revenue	$6.2M	↑ 120.63%
Net Income	$-85.0M	↑ 95.08%
Net Profit Margin	-1.4K%	↑ 178.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$874.0K	↑ 91.25%
Net Income	$-13.7M	↑ 30.15%
Net Profit Margin	-1.6K%	↑ 738.38%

	Q2 FY24	Q/Q Change
Revenue	$1.9M	↑ 113.16%
Net Income	$-17.6M	↑ 28.07%
Net Profit Margin	-945.09%	↑ 627.91%

	Q3 FY24	Q/Q Change
Revenue	$2.2M	↑ 16.59%
Net Income	$-25.2M	↑ 42.98%
Net Profit Margin	-1.2K%	↓ 213.93%

	Q4 FY24	Q/Q Change
Revenue	$1.3M	↓ 38.95%
Net Income	$-28.4M	↑ 12.97%
Net Profit Margin	-2.1K%	↓ 985.78%

	Q1 FY25	Q/Q Change
Revenue	$1.2M	↓ 12.29%
Net Income	$-29.5M	↑ 3.77%
Net Profit Margin	-2.5K%	↓ 392.69%

	Q2 FY25	Q/Q Change
Revenue	$193.0K	↓ 83.4%
Net Income	$-31.6M	↑ 7.18%
Net Profit Margin	-16.4K%	↓ 13850.59%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-1.8M	↑ 110.63%

	FY20	Y/Y Change
Profit	$-2.0M	↑ 7.33%

	FY21	Y/Y Change
Profit	$-544.0K	↓ 72.5%

	FY22	Y/Y Change
Profit	$6.3M	↓ 1252.57%

	FY23	Y/Y Change
Profit	$2.8M	↓ 54.93%

	FY24	Y/Y Change
Profit	$6.2M	↑ 120.63%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$874.0K	↑ 91.25%

	Q2 FY24	Q/Q Change
Profit	$1.9M	↑ 113.16%

	Q3 FY24	Q/Q Change
Profit	$2.2M	↑ 16.59%

	Q4 FY24	Q/Q Change
Profit	$1.3M	↓ 38.95%

	Q1 FY25	Q/Q Change
Profit	$1.2M	↓ 12.29%

	Q2 FY25	Q/Q Change
Profit	$94.0K	↓ 91.92%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-57.1M	↑ 36.33%
Investing Cash Flow	$1.5M	↓ 101.67%
Financing Cash Flow	$62.3M	↓ 56.17%

	FY20	Y/Y Change
Operating Cash Flow	$-64.0M	↑ 12.12%
Investing Cash Flow	$-10.6M	↓ 794.19%
Financing Cash Flow	$67.7M	↑ 8.74%

	FY21	Y/Y Change
Operating Cash Flow	$-59.5M	↓ 7.02%
Investing Cash Flow	$43.4M	↓ 508.35%
Financing Cash Flow	$89.6M	↑ 32.27%

	FY22	Y/Y Change
Operating Cash Flow	$-29.1M	↓ 51.17%
Investing Cash Flow	$-59.8M	↓ 237.74%
Financing Cash Flow	$96.7M	↑ 7.9%

	FY23	Y/Y Change
Operating Cash Flow	$-36.9M	↑ 26.8%
Investing Cash Flow	$20.3M	↓ 133.86%
Financing Cash Flow	$133.6M	↑ 38.17%

	FY24	Y/Y Change
Operating Cash Flow	$-78.2M	↑ 112.09%
Investing Cash Flow	$-286.8M	↓ 1516.15%
Financing Cash Flow	$255.6M	↑ 91.37%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-14.9M	↑ 26.04%
Investing Cash Flow	$-5.5M	↓ 33.14%
Financing Cash Flow	$217.8M	↓ 4577.84%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-14.5M	↓ 2.76%
Investing Cash Flow	$1.2M	↓ 121.23%
Financing Cash Flow	$-2.2M	↓ 101.01%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-8.6M	↓ 40.85%
Investing Cash Flow	$-259.4M	↓ 22286.83%
Financing Cash Flow	$296.0K	↓ 113.48%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-27.4M	↑ 219.38%
Investing Cash Flow	$-23.1M	↓ 91.09%
Financing Cash Flow	$39.7M	↑ 13304.05%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-27.6M	↑ 0.68%
Investing Cash Flow	$14.8M	↓ 164.02%
Financing Cash Flow	$161.0K	↓ 99.59%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-23.9M	↓ 13.53%
Investing Cash Flow	$26.4M	↑ 78.75%
Financing Cash Flow	$568.0K	↑ 252.8%

Magenta Therapeutics Technicals Summary

Sell

Neutral

Buy

Magenta Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Magenta Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Magenta Therapeutics Inc	9.79%	-2.44%	-21.43%	-14.78%	221.16%
Regeneron Pharmaceuticals, Inc.	4.65%	-16.73%	-52.11%	-6.73%	-5.71%
Beone Medicines Ltd	7.16%	32.17%	61.08%	80.84%	30.07%
Vertex Pharmaceuticals Incorporated	-14.79%	-17.19%	-19.84%	32.96%	44.01%
Alnylam Pharmaceuticals, Inc.	43.03%	83.01%	63.29%	110.39%	235.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Magenta Therapeutics Inc	3.24	NA	NA	-3.37	-0.35	-0.23	NA	9.42
Regeneron Pharmaceuticals, Inc.	14.47	14.47	1.18	39.36	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.73	27.73	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Magenta Therapeutics Inc	Buy	$674.7M	221.16%	3.24	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$60.8B	-5.71%	14.47	31.37%
Beone Medicines Ltd	NA	$39.3B	30.07%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.0B	44.01%	27.73	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.62%	NA	-12.96%

About Magenta Therapeutics Inc

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Organization	Magenta Therapeutics
Employees	78
CEO	Mr. Marino Garcia M.B.A.
Industry	Miscellaneous

Key Management of Magenta Therapeutics Inc

Name	Title
Mr. Marino Garcia M.B.A.	President, CEO & Director
Mr. Ryan Savitz	Chief Financial Officer & Chief Business Officer
Mr. Simrat Randhawa M.B.A., M.D.	Chief Medical Officer
Mr. Edward G. Carr	Chief Accounting Officer
Mr. Judson Taylor	Senior VP & Head of Technical Operations
Ms. Jennifer Davis Ruff	VP and Head of Investor Relations & Corporate Affairs
Mr. Adam M. Veness Esq.	Senior VP, General Counsel & Secretary
Ms. Kristina Maximenko	Chief People Officer
Ms. Rashieda Gluck	Head of Clinical Development Operations
Mr. Scott Nogi M.B.A.	Head of Business Operations

Important FAQs about investing in DNTH Stock from India :

What is Magenta Therapeutics share price today?

Magenta Therapeutics share price today is $23.50 as on August 20, 2025 at 11:37 PM IST. Magenta Therapeutics share today touched a day high of $23.50 and a low of $22.53.

What is the 52 week high and 52 week low for Magenta Therapeutics share?

Magenta Therapeutics share touched a 52 week high of $32.27 and a 52 week low of $13.37. Magenta Therapeutics stock price today i.e. August 20, 2025 at 11:37 PM IST is trending at $23.50, lower by 27.18% versus the 52 week high.

How to invest in Magenta Therapeutics Stock (DNTH) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Magenta Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Magenta Therapeutics Shares that will get you 0.0638 shares as per Magenta Therapeutics share price of $23.50 per share as on August 20, 2025 at 11:37 PM IST.

What is the minimum amount required to buy Magenta Therapeutics Stock (DNTH) from India?

Indian investors can start investing in Magenta Therapeutics (DNTH) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in Magenta Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Magenta Therapeutics share’s latest price of $23.50 as on August 20, 2025 at 11:37 PM IST, you will get 0.4255 shares of Magenta Therapeutics. Learn more about fractional shares .

What are the returns that Magenta Therapeutics has given to Indian investors in the last 5 years?

Magenta Therapeutics stock has given 221.16% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?